<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15689">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902640</url>
  </required_header>
  <id_info>
    <org_study_id>ML30018</org_study_id>
    <nct_id>NCT02902640</nct_id>
  </id_info>
  <brief_title>An Observational Study to Assess Safety of Sulfamethoxazole + Trimethoprim + Guaifenesin (Balsamic Bactrim) in Adult Participants With Acute Bronchitis</brief_title>
  <official_title>A Pilot, Multicentric and Observational Study of Safety of Sulfamethoxazole + Trimethoprim + Guaifenesin (Balsamic Bactrim) in Adult Patients With Acute Bronchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a pilot, observational and multicentric study of safety of sulfamethoxazole plus (+)
      trimethoprim + guaifenesin (Balsamic Bactrim) in adult participants with acute bronchitis.
      Overall, 50 adult participants with acute bronchitis eligible for treatment with
      sulfamethoxazole + trimethoprim + guaifenesin will be enrolled. Administration of Balsamic
      Bactrim will be according to physician's recommendation under local labeling.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with adverse events related to sulfamethoxazole + trimethoprim + guaifenesin (as assessed by the investigator)</measure>
    <time_frame>From baseline up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Percentage of Participants With Balsamic Bactrim Dose Change (Increase or Decrease)</measure>
    <time_frame>From baseline up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Balsamic Bactrim Dose Change by Reason for Change</measure>
    <time_frame>From baseline up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Change in Balsamic Bactrim Frequency of Administration</measure>
    <time_frame>From baseline up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Balsamic Bactrim Dose Interruption</measure>
    <time_frame>From baseline up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Balsamic Bactrim Treatment Discontinuation</measure>
    <time_frame>From baseline up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Balsamic Bactrim Treatment Reintroduction After Discontinuation</measure>
    <time_frame>From baseline up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Compliance to Balsamic Bactrim Treatment According to Local Label, as Assessed by Treating Physician</measure>
    <time_frame>From baseline up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Predisposing Factors (Categories) for Safety (No specific pre-defined factors, these will be decided based on observations during study)</measure>
    <time_frame>From baseline up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bronchitis</condition>
  <arm_group>
    <arm_group_label>Acute Bronchitis Participants</arm_group_label>
    <description>Participants with acute bronchitis for whom the treating physician has decided to initiate treatment with Balsamic Bactrim, will be observed. Administration of Balsamic Bactrim will be according to physician's recommendation under local labeling. The study protocol does not enforce any treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guaifenesin</intervention_name>
    <description>Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.</description>
    <arm_group_label>Acute Bronchitis Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamethoxazole</intervention_name>
    <description>Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.</description>
    <arm_group_label>Acute Bronchitis Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim</intervention_name>
    <description>Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.</description>
    <arm_group_label>Acute Bronchitis Participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants receiving treatment for acute bronchitis with Balsamic Bactrim
        according to standard of care and in line with the current summary of product
        characteristics (SPC) / local labeling and who have no contraindication to Balsamic
        Bactrim as per the local label.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants starting treatment with Balsamic Bactrim as per treating physician's
             discretion

          -  Participants with a clinical diagnosis of acute bronchitis (Cough with or without
             sputum production less than 30 days)

        Exclusion Criteria:

          -  Participants who have started treatment with another antibiotic at the time of the
             visit

          -  Participants with no respiratory infections

          -  Participants with mental disorders

          -  Participants with severe hepatic parenchymal damage

          -  Participants with severe renal failure if the drug plasma concentration cannot be
             monitored

          -  Participants with hypersensitivity to any of its active ingredients or excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML30018 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clínica Providencia; Centro de Investigación de Enfermedades Respiratorias</name>
      <address>
        <city>Lima</city>
        <zip>15088</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Medicas/Hospital Maria Auxiliadora</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 29</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica de Especialidades Medicas</name>
      <address>
        <city>Lima</city>
        <zip>Lima 41</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica San Borja; Instituto de Enfermedades Respiratorias EFEH</name>
      <address>
        <city>Lima</city>
        <zip>Lima 41</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>September 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Guaifenesin</mesh_term>
    <mesh_term>Phenylpropanolamine</mesh_term>
    <mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
